Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. drug resistant
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • This Year
  • Older

Drug Resistant Articles & Analysis

110 news found

Infection Control Resources to Identify Shigella and Other Pathogens in Puerto Rico

Infection Control Resources to Identify Shigella and Other Pathogens in Puerto Rico

Unfortunately, a growing number of these infections involve drug-resistant Shigella. The four species of Shigella listed by the CDC include: Shigella sonnei (the most common species in the United States) Shigella flexneri Shigella boydii Shigella dysenteriae “Shigella spreads easily, and it can be transmitted from one person to another, or through ...

ByCochrane & Associates, LLC


CD Bioparticles Launches Advanced Bio-Targeted Small Molecules Conjugated Magnetic Nanoparticles for Targeted Cancer Therapy

CD Bioparticles Launches Advanced Bio-Targeted Small Molecules Conjugated Magnetic Nanoparticles for Targeted Cancer Therapy

Combined with nanotechnology, "smart" drugs can actively target tumors by binding to corresponding receptors on tumor cells through interactions with phenotype-specific ligands conjugated to the delivery vehicle. ...

ByCD Bioparticles


Profacgen Updates Its Antimicrobial Peptides Services to Drive Innovation in Antimicrobial Research

Profacgen Updates Its Antimicrobial Peptides Services to Drive Innovation in Antimicrobial Research

Profacgen, a leading provider of custom biotechnology services, is pleased to announce significant updates to its Antimicrobial Peptides (AMPs) Services, enhancing its capabilities to support the growing demand for alternative therapies in the fight against drug-resistant pathogens. As antibiotic resistance continues to pose a global health ...

ByProfacgen


Advancing Tuberculosis Treatment: The Role of flexiVent In Evaluating Bacteriophage Therapy

Advancing Tuberculosis Treatment: The Role of flexiVent In Evaluating Bacteriophage Therapy

The rise of antibiotic-resistant bacteria has driven renewed interest in alternative treatments, including phage therapy. A recent study by Yang, F., et al (2024) explores the potential of bacteriophage therapy for treating multi-drug resistant Mycobacterium tuberculosis (Mtb) infections using humanized mouse models. ...

BySCIREQ - an emka TECHNOLOGIES Company


CD Formulation Leads the Way in Antiserum Preparation

CD Formulation Leads the Way in Antiserum Preparation

Antibacterial Serum Preparation Bacterial infections remain a significant concern globally, and the emergence of antibiotic-resistant strains has heightened this challenge. CD Formulation addresses this urgent issue with its antibacterial serum preparation services. ...

ByCD Formulation


World TB Day and Infection Control Resources in New York City to Help Prevent New Cases

World TB Day and Infection Control Resources in New York City to Help Prevent New Cases

As recently as 2022, the agency reports there were 536 confirmed TB cases, including some involving multi-drug resistant (MDR) TB, and that 100% of NYC neighborhoods had at least one TB case. ...

ByCochrane & Associates, LLC


Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting

Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting

Darolutamide, which is jointly developed by Bayer and Orion Corporation, is an oral androgen receptor inhibitor indicated for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease and for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC). ...

ByBayer AG


CD ComputaBio Boosts Small Molecule Drug Development with Protein-Small Molecule Docking Service

CD ComputaBio Boosts Small Molecule Drug Development with Protein-Small Molecule Docking Service

It plays a crucial role in drug design and screening, as it enables modeling and prediction of interactions between proteins and small molecules, allowing customers to better understand drug mechanisms of action and optimize candidate compounds. ...

ByCD ComputaBio


A Phase Ii Trial Of Onapristone In Combination With Fulvestrant For Patients With Er-Positive And Her2-Negative Metastatic Breast Cancer After Progression On Endocrine Therapy And Cdk 4/6 Inhibitors

A Phase Ii Trial Of Onapristone In Combination With Fulvestrant For Patients With Er-Positive And Her2-Negative Metastatic Breast Cancer After Progression On Endocrine Therapy And Cdk 4/6 Inhibitors

Antiprogestins act as Progesterone Receptor (PgR) antagonists. Novel and promising class of drugs to overcome endocrine resistance associated with ESR1 mutations. ...

ByContext Therapeutics Inc.


Candida auris and Infection Control Resources for Healthcare Providers

Candida auris and Infection Control Resources for Healthcare Providers

Candida auris is an emerging multidrug-resistant microorganism that was first identified in 2009 in Asia. It has quickly become a cause of severe infections around the world, including in the United States according to the Centers for Disease Control and Prevention (CDC). ...

ByCochrane & Associates, LLC


Starton Therapeutics’ STAR-LLD Continuous Delivery Shows Superior Tumor Reduction and Progression Free Survival (PFS) Compared to Pulsatile Lenalidomide Treatment in Lenalidomide-Resistant Model

Starton Therapeutics’ STAR-LLD Continuous Delivery Shows Superior Tumor Reduction and Progression Free Survival (PFS) Compared to Pulsatile Lenalidomide Treatment in Lenalidomide-Resistant Model

Starton Therapeutics Inc., (the “Company”) a clinical stage biotechnology company announced today results from a 28-day efficacy study of STAR-LLD continuous subcutaneous (SC) infusion versus intraperitoneal (IP) lenalidomide in immunomodulatory drug (IMiD)-resistant RPMI CB.17 SCID mice. In this preclinical study: continuous delivery of lenalidomide ...

ByStarton Therapeutics


ASH 2022: Cellworks Biosimulation Study Reveals Biomarkers that Predict Response to Hypomethylating Agents and Patient Survival in MDS

ASH 2022: Cellworks Biosimulation Study Reveals Biomarkers that Predict Response to Hypomethylating Agents and Patient Survival in MDS

“This study demonstrates the power of using Cellworks personalized therapy biosimulation to gain insight into individual patient mutanome, drug resistance pathways and novel biomarkers that determine their drug response and resistance to better inform treatment decisions for MDS ...

ByCellworks Research India Private Limited


Lumen Bioscience Awarded $3.6 Million by U.S. Army to Advance Low-cost, Scalable Preventative for Antibiotic-Resistant Infections

Lumen Bioscience Awarded $3.6 Million by U.S. Army to Advance Low-cost, Scalable Preventative for Antibiotic-Resistant Infections

This preventative approach will allow Lumen to develop an inexpensive, biologic drug cocktail against the most frequent, multi-drug resistant infecting pathogens. The therapeutic product would be administered and be designed to mitigate risks of antibiotic-resistant infections in resource constrained settings such as battlefield ...

ByLumen Bioscience, Inc.


Creative Proteomics Metabolomics Unveils Drug-Resistant Metabolomics Research Service

Creative Proteomics Metabolomics Unveils Drug-Resistant Metabolomics Research Service

Drug therapy is one of the major modalities for cancer treatment. However, drug resistance may reveal whether it is chemotherapy drugs, targeted drugs, or immunotherapy drugs. Once drug resistance (especially multidrug resistance) is developed, ...

ByCreative Proteomics


MicrobioSeq Announces the Launch of the Phage Whole-Genome Sequencing Service

MicrobioSeq Announces the Launch of the Phage Whole-Genome Sequencing Service

These sequencing technologies are also tools for understanding biochemical interactions between prokaryotes and phages and have been widely used in the food industry and medical research. For example, multiple drug resistance (MDR) has risen dramatically, and phage therapy may be an effective way to treat bacterial infections. ...

ByCD Genomics


Flowonix Medical Inc. And Cerebral Therapeutics Announce World-First Clinical Trial Delivering Medication Directly Into The Brain For Patients With Refractory Epilepsy

Flowonix Medical Inc. And Cerebral Therapeutics Announce World-First Clinical Trial Delivering Medication Directly Into The Brain For Patients With Refractory Epilepsy

The jointly developed therapy features a micro-infusion device that tightly controls drug delivery to a region of the brain for patients with medically refractory epilepsy. ...

ByFlowonix Medical Inc.


Photodisinfection successfully eradicates pathogens associated with replacement joint infections

Photodisinfection successfully eradicates pathogens associated with replacement joint infections

Importantly, photodisinfection is effective against drug-resistant pathogens and does not cause resistance-formation, both distinct advantages over antibiotics. ...

ByOndine Biomedical Inc


Ondine’s photodisinfection kills ESKAPE pathogens

Ondine’s photodisinfection kills ESKAPE pathogens

“Overuse of antibiotics over decades has caused adaptation in many microbes, and we now see multidrug resistance (MDR) evolving into extensive drug resistance (XDR) in bacteria, rendering even the most powerful drugs we have ineffective,” stated Dr. ...

ByOndine Biomedical Inc


Aesther Healthcare Acquisition Corp. Has Entered Into an Agreement and Plan of Merger with Ocean Biomedical, Inc., a Next-Generation Biopharma Company, to List on NASDAQ

Aesther Healthcare Acquisition Corp. Has Entered Into an Agreement and Plan of Merger with Ocean Biomedical, Inc., a Next-Generation Biopharma Company, to List on NASDAQ

However, only a minority of patients that get these drugs respond to them and the responses that are seen are often not durable. ...

ByOcean Biomedical


Alexandra Clyde appointed to Sequana Medical Board of Directors

Alexandra Clyde appointed to Sequana Medical Board of Directors

Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces the appointment of Alexandra Clyde as an independent Non-Executive Director of the Company. ...

BySequana Medical NV

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT